Literature DB >> 19355944

Multiple myeloma bone marrow niche.

Grzegorz Wladyslaw Basak1, Anand S Srivastava, Rakesh Malhotra, Ewa Carrier.   

Abstract

"Niche" is defined as a specialized regulatory microenvironment, consisting of components which control the fate specification of stem and progenitor cells, as well as maintaining their development by supplying the requisite factors. Bone marrow (BM) niche has a well-organized architecture and is composed of osteoblasts, osteoclasts, bone marrow endothelial cells, stromal cells, adipocytes and extracellular matrix proteins (ECM). These elements play an essential role in the survival, growth and differentiation of diverse lineages of blood cells, but also provide optimal growth environment for multiple hematological malignancies including multiple myeloma (MM). MM is a neoplastic plasma cell disorder which not only resides in BM but also converts it into specialized neoplastic niche. This niche aids the growth and spreading of tumor cells by a complex interplay of cytokines, chemokines, proteolytic enzymes and adhesion molecules. Moreover, the MM BM microenvironment was shown to confer survival and chemoresistance of MM cells to current therapies. However, our knowledge in this field is still in infancy and many details are unknown. Therefore, there is a strong need to further dissect the MM BM niche and understand the process of how the complex interactions with BM milieu influence MM growth, survival and development of resistance to chemotherapy. A better and more detailed understanding of neoplastic MM niche will provide a guiding model for identifying and validating novel targeted therapies directed against MM. Therefore, in the present review, we have focused principally on the basic features, physical structures, and functions of the BM niche and have highlighted its interaction with MM cells.

Entities:  

Mesh:

Year:  2009        PMID: 19355944     DOI: 10.2174/138920109787847493

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  37 in total

1.  Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.

Authors:  Lavinia Raimondi; Angela De Luca; Nicola Amodio; Mauro Manno; Samuele Raccosta; Simona Taverna; Daniele Bellavia; Flores Naselli; Simona Fontana; Odessa Schillaci; Roberto Giardino; Milena Fini; Pierfrancesco Tassone; Alessandra Santoro; Giacomo De Leo; Gianluca Giavaresi; Riccardo Alessandro
Journal:  Oncotarget       Date:  2015-05-30

Review 2.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

Review 3.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

4.  Relevance of the myeloid differentiation factor 88 (MyD88) on RANKL, OPG, and nod expressions induced by TLR and IL-1R signaling in bone marrow stromal cells.

Authors:  Fábio Renato Manzolli Leite; Sabrina Garcia de Aquino; Morgana Rodrigues Guimarães; Joni Augusto Cirelli; Dario S Zamboni; João S Silva; Carlos Rossa Junior
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 5.  Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Franco Dammacco; Franco Silvestris
Journal:  Oncologist       Date:  2011-06-09

6.  The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Authors:  M A Hurchla; A Garcia-Gomez; M C Hornick; E M Ocio; A Li; J F Blanco; L Collins; C J Kirk; D Piwnica-Worms; R Vij; M H Tomasson; A Pandiella; J F San Miguel; M Garayoa; K N Weilbaecher
Journal:  Leukemia       Date:  2012-07-05       Impact factor: 11.528

7.  Cancer stem cell and stromal microenvironment.

Authors:  Li Li; John Cole; David A Margolin
Journal:  Ochsner J       Date:  2013

8.  Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model.

Authors:  Jaehyup Kim; Esmail D Zanjani; Christine M Jeanblanc; A Daisy Goodrich; Peiman Hematti
Journal:  Exp Hematol       Date:  2013-04-20       Impact factor: 3.084

9.  Cell Trafficking in Multiple Myeloma.

Authors:  Giada Bianchi; Shaji Kumar; Irene M Ghobrial; Aldo M Roccaro
Journal:  Open J Hematol       Date:  2012-02-21

10.  Osteotropic Radiolabeled Nanophotosensitizer for Imaging and Treating Multiple Myeloma.

Authors:  Rui Tang; Alexander Zheleznyak; Matthew Mixdorf; Anchal Ghai; Julie Prior; Kvar C L Black; Monica Shokeen; Nathan Reed; Pratim Biswas; Samuel Achilefu
Journal:  ACS Nano       Date:  2020-04-06       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.